Sakar Healthcare Limited
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products
What Sakar files
- Others33
- Updates18
- Board Meeting16
- Investor Meet15
- Important15
- Results4
Sakar Healthcare received 14 new oncology product approvals in EU, UK, and Canada with 7 partners. This expands cancer treatment coverage, positioning the company to boost top-line sales.
Sakar Healthcare's Q1 revenue surged 38% YoY to ₹72.97 Cr, with PAT skyrocketing 120% to ₹10.28 Cr. The company secured 16 Marketing Authorisations and initiated 33 tech transfer projects, bolstering its oncology platform and global reach.
SAKAR Healthcare has announced a board meeting on 24th July, 2026, to approve the financial results for the quarter ended 30th June, 2026. The trading window remains closed for designated persons until 48 hours after results declaration.
SAKAR HEALTHCARE has filed its dematerialization compliance certificate for the recent quarter, confirming all shareholder security processes meet requirements.
Sakar Healthcare signed its 40th oncology agreement with Zydus Lifesciences for GCC & emerging markets. Secured 5 EU Marketing Authorizations and 5 site variation approvals. In-house API development strengthens its integrated, regulatory-led business.